{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T11:21:04Z","timestamp":1774783264886,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,29]]},"DOI":"10.7759\/cureus.106047","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T07:30:31Z","timestamp":1774769431000},"source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Nucleos(t)ide Analogue Discontinuation in Noncirrhotic Patients With Chronic Hepatitis B: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Shrey","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ujjwal","family":"Sonika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesh","family":"Vaithiyam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deep","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barjesh Chander","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16968","article-title":"Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96\u2009weeks is associated with low baseline HBsAg levels","volume":"56","author":"Hall SA","year":"2022","unstructured":"Hall SA, Burns GS, Anagnostou D, et al.. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96\u2009weeks is associated with low baseline HBsAg levels. Aliment Pharmacol Ther. 2022, 56:310-20. 10.1111\/apt.16968","journal-title":"Aliment Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto WK","year":"2015","unstructured":"Seto WK, Hui AJ, Wong VW, et al.. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut. 2015, 64:667-72. 10.1136\/gutjnl-2014-307237","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis G","year":"2016","unstructured":"Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, Petersen J. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology. 2016, 63:1481-92. 10.1002\/hep.28438","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel F","year":"2023","unstructured":"van B\u00f6mmel F, Stein K, Heyne R, et al.. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. J Hepatol. 2023, 78:926-36. 10.1016\/j.jhep.2022.12.018","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT\u2011B study)","volume":"162","author":"Hirode G","year":"2022","unstructured":"Hirode G, Choi HS, Chen CH, et al.. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT\u2011B study). Gastroenterology. 2022, 162:757-71. 10.1053\/j.gastro.2021.11.002","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao JH","year":"2021","unstructured":"Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021, 15:833-51. 10.1007\/s12072-021-10223-5","journal-title":"Hepatol Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin SK","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al.. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016, 10:1-98. 10.1007\/s12072-015-9675-4","journal-title":"Hepatol Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault NA","year":"2018","unstructured":"Terrault NA, Lok AS, McMahon BJ, et al.. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018, 67:1560-99. 10.1002\/hep.29800","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017, 67:370-98. 10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025, 83:502-83. 10.1016\/j.jhep.2025.03.018","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7534-2","article-title":"Hepatitis B vaccination coverage across India: exploring the spatial heterogeneity and contextual determinants","volume":"19","author":"Khan J","year":"2019","unstructured":"Khan J, Shil A, Mohanty SK. Hepatitis B vaccination coverage across India: exploring the spatial heterogeneity and contextual determinants. BMC Public Health. 2019, 19:1263. 10.1186\/s12889-019-7534-2","journal-title":"BMC Public Health"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.04.014","article-title":"Hepatitis B prevalence and risk factors in Punjab, India: a population-based serosurvey","volume":"12","author":"Shadaker S","year":"2022","unstructured":"Shadaker S, Sood A, Averhoff F, et al.. Hepatitis B prevalence and risk factors in Punjab, India: a population-based serosurvey. J Clin Exp Hepatol. 2022, 12:1310-9. 10.1016\/j.jceh.2022.04.014","journal-title":"J Clin Exp Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1039696","article-title":"Hepatitis B virus infection among the tribal and particularly vulnerable tribal population from an eastern state of India: findings from the serosurvey in seven tribal dominated districts, 2021-2022","volume":"14","author":"Bhattacharya H","year":"2023","unstructured":"Bhattacharya H, Parai D, Sahoo SK, et al.. Hepatitis B virus infection among the tribal and particularly vulnerable tribal population from an eastern state of India: findings from the serosurvey in seven tribal dominated districts, 2021-2022. Front Microbiol. 2023, 14:1039696. 10.3389\/fmicb.2023.1039696","journal-title":"Front Microbiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2023.08.008","article-title":"Long term HBsAg responses to Peg-interferon alpha-2b in HBeAg negative chronic hepatitis B patients developing clinical relapse after stopping long-term nucleos(t)ide analogue therapy","volume":"14","author":"Kumar K","year":"2024","unstructured":"Kumar K, Jindal A, Gupta E, et al.. Long term HBsAg responses to Peg-interferon alpha-2b in HBeAg negative chronic hepatitis B patients developing clinical relapse after stopping long-term nucleos(t)ide analogue therapy. J Clin Exp Hepatol. 2024, 14:101272. 10.1016\/j.jceh.2023.08.008","journal-title":"J Clin Exp Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000098","article-title":"Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN","volume":"7","author":"Islam M","year":"2023","unstructured":"Islam M, Kumar K, Sevak JK, et al.. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN. Hepatol Commun. 2023, 7:e0098. 10.1097\/HC9.0000000000000098","journal-title":"Hepatol Commun"},{"key":"ref16","article-title":"Cessation of nucleoside\/nucleotide analogue therapy in chronic hepatitis B HBeAg-negative patients","volume":"18","author":"Pockros PJ","year":"2022","unstructured":"Pockros PJ, Mulgaonkar A. Cessation of nucleoside\/nucleotide analogue therapy in chronic hepatitis B HBeAg-negative patients. Gastroenterol Hepatol (N Y). 2022, 18:320-5.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis SJ","year":"2012","unstructured":"Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology. 2012, 143:629-36. 10.1053\/j.gastro.2012.05.039","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13150","article-title":"Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B","volume":"41","author":"Chi H","year":"2015","unstructured":"Chi H, Hansen BE, Yim C, et al.. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2015, 41:867-76. 10.1111\/apt.13150","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac409","article-title":"Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation","volume":"78","author":"Tseng TN","year":"2023","unstructured":"Tseng TN, Jeng WJ, Hu TH, Wang JH, Hung CH, Lu SN, Chen CH. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. J Antimicrob Chemother. 2023, 78:436-9. 10.1093\/jac\/dkac409","journal-title":"J Antimicrob Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/476041-outcomes-of-nucleostide-analogue-discontinuation-in-noncirrhotic-patients-with-chronic-hepatitis-b-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T07:30:32Z","timestamp":1774769432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/476041-outcomes-of-nucleostide-analogue-discontinuation-in-noncirrhotic-patients-with-chronic-hepatitis-b-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.106047","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,29]]}}}